Skip to Content
 
Vandana G.  Abramson

Vandana G. Abramson, M.D.

Associate Professor of Medicine (Hematology/Oncology)

  • Appointments
    615-322-2064
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Vanderbilt Breast Center at One Hundred Oaks
    (615) 322-2064

    Office
    615-936-3831
  • Faxes
    Vanderbilt Breast Center at One Hundred Oaks Fax
    (615) 343-3343
    Office Fax
    615-343-7602
    Clinic Fax
    615-343-0099
  • Addresses
    Vanderbilt Breast Center at One Hundred Oaks
    719 Thompson Lane, Suite 25000
    Nashville, TN 37204
    Website

    Office
    Division of Hematology/Oncology
    2220 Pierce Avenue, 777 PRB
    Nashville, TN 37232-6307
Profile

Dr. Abramson is an Assistant Professor of Medicine in the Division of Hematology/Oncology. After receiving her B.A. in English and Molecular & Cell Biology at the University of California, Berkeley, she went to medical school at the University of Chicago. Dr. Abramson completed her Internal Medicine Residency at Brigham and Women's Hospital in Boston, MA and Hematology/Oncology training at the University of Pennsylvania in Philadelphia, PA.

Dr. Abramson serves as the Principal Investigator on several breast cancer clinical trials at Vanderbilt. She is an active member in the American Society of Clinical Oncology.

Education
 
  • M.D.: University of Chicago School of Medicine
  • Residency: Brigham and Women's Hospital, Boston
  • Fellowship: Hospital of the University of Pennsylvania
 
Publications
  • Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL. Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clin. Cancer Res [print-electronic]. 2017 Jul 7/15/2017; 23(14): 3520-8. PMID: 28031425, PII: 1078-0432.CCR-16-1764, DOI: 10.1158/1078-0432.CCR-16-1764, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28031425.
  • Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin. Cancer Res [print-electronic]. 2017 Mar 3/7/2017; PMID: 28270498, PII: 1078-0432.CCR-16-3055, DOI: 10.1158/1078-0432.CCR-16-3055, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28270498.
  • Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL. A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin. Cancer Res [print-electronic]. 2017 Jan 1/1/2017; 23(1): 26-34. PMID: 27126994, PMCID: PMC5085926, PII: 1078-0432.CCR-16-0134, DOI: 10.1158/1078-0432.CCR-16-0134, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27126994.
  • Williams JM, Arlinghaus LR, Rani SD, Shone MD, Abramson VG, Pendyala P, Chakravarthy AB, Gorge WJ, Knowland JG, Lattanze RK, Perrin SR, Scarantino CW, Townsend DW, Abramson RG, Yankeelov TE. Towards real-time topical detection and characterization of FDG dose infiltration prior to PET imaging. Eur. J. Nucl. Med. Mol. Imaging [print-electronic]. 2016 Dec; 43(13): 2374-80. PMID: 27557845, PMCID: PMC5096989, PII: 10.1007/s00259-016-3477-3, DOI: 10.1007/s00259-016-3477-3, ISSN: 1619-7089.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27557845.
  • Henry NL, Somerfield MR, Abramson VG, Allison KH, Anders CK, Chingos DT, Hurria A, Openshaw TH, Krop IE. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. J. Clin. Oncol [print-electronic]. 2016 Jul 7/1/2016; 34(19): 2303-11. PMID: 27001586, PII: JCO.2015.65.8609, DOI: 10.1200/JCO.2015.65.8609, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27001586.
  • Colonna SV, Higgins AK, Alvarez J, Saville BR, Lawrence J, Abramson VG. Analysis of Risk of Recurrence by Subtype in = 1-cm Breast Tumors. Clin. Breast Cancer [print-electronic]. 2016 Jun; 16(3): 223-31. PMID: 26683741, PII: S1526-8209(15)00239-6, DOI: 10.1016/j.clbc.2015.10.001, ISSN: 1938-0666.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26683741.
  • Abramson RG, Lambert KF, Jones-Jackson LB, Arlinghaus LR, Williams J, Abramson VG, Chakravarthy AB, Yankeelov TE. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer. Acad Radiol [print-electronic]. 2015 Jul; 22(7): 853-9. PMID: 25865435, PMCID: PMC4464958, PII: S1076-6332(15)00109-9, DOI: 10.1016/j.acra.2015.02.012, ISSN: 1878-4046.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25865435.
  • Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, . TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin. Cancer Res [print-electronic]. 2015 Jun 6/15/2015; 21(12): 2722-9. PMID: 25779953, PII: 1078-0432.CCR-14-2780, DOI: 10.1158/1078-0432.CCR-14-2780, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25779953.
  • Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF, . Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin. Cancer Res [print-electronic]. 2015 Jun 6/15/2015; 21(12): 2771-9. PMID: 25779948, PMCID: PMC5521206, PII: 1078-0432.CCR-14-2781, DOI: 10.1158/1078-0432.CCR-14-2781, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25779948.
  • Ballinger TJ, Sanders ME, Abramson VG. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy. Clin. Breast Cancer [print-electronic]. 2015 Jun; 15(3): 171-80. PMID: 25516402, PII: S1526-8209(14)00267-5, DOI: 10.1016/j.clbc.2014.11.009, ISSN: 1938-0666.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25516402.
  • Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson VG, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Yankeelov TE. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer. Invest Radiol. 2015 Apr; 50(4): 195-204. PMID: 25360603, PMCID: PMC4471951, DOI: 10.1097/RLI.0000000000000100, ISSN: 1536-0210.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25360603.
  • Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer [print-electronic]. 2015 Jan 1/1/2015; 121(1): 8-16. PMID: 25043972, PMCID: PMC4270831, DOI: 10.1002/cncr.28914, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25043972.
  • Abramson VG, Mayer IA. Molecular Heterogeneity of Triple Negative Breast Cancer. Curr Breast Cancer Rep. 2014 Sep 9/1/2014; 6(3): 154-8. PMID: 25419441, PMCID: PMC4235783, DOI: 10.1007/s12609-014-0152-1, ISSN: 1943-4588.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25419441.
  • Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24722917.
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823.
  • Atuegwu NC, Li X, Arlinghaus LR, Abramson RG, Williams JM, Chakravarthy AB, Abramson VG, Yankeelov TE. Longitudinal, intermodality registration of quantitative breast PET and MRI data acquired before and during neoadjuvant chemotherapy: preliminary results. Med Phys. 2014 May; 41(5): 52302. PMID: 24784395, PMCID: PMC4000383, DOI: 10.1118/1.4870966, ISSN: 0094-2405.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24784395.
  • Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol [print-electronic]. 2014 Apr 4/20/2014; 32(12): 1202-9. PMID: 24663045, PMCID: PMC3986383, PII: JCO.2013.54.0518, DOI: 10.1200/JCO.2013.54.0518, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24663045.
  • Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med [print-electronic]. 2014 Apr; 71(4): 1592-602. PMID: 23661583, PMCID: PMC3742614, DOI: 10.1002/mrm.24782, ISSN: 1522-2594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23661583.
  • Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin. Cancer Res. 2014 Feb 2/15/2014; 20(4): 782-90. PMID: 24536073, PMCID: PMC3962777, PII: 1078-0432.CCR-13-0583, DOI: 10.1158/1078-0432.CCR-13-0583, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24536073.
  • Li X, Kang H, Arlinghaus LR, Abramson RG, Chakravarthy AB, Abramson VG, Farley J, Sanders M, Yankeelov TE. Analyzing Spatial Heterogeneity in DCE- and DW-MRI Parametric Maps to Optimize Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer. Transl Oncol. 2014 Feb; 7(1): 14-22. PMID: 24772203, PMCID: PMC3998687, ISSN: 1936-5233.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24772203.
  • Abramson RG, Li X, Hoyt TL, Su PF, Arlinghaus LR, Wilson KJ, Abramson VG, Chakravarthy AB, Yankeelov TE. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. Magn Reson Imaging [print-electronic]. 2013 Nov; 31(9): 1457-64. PMID: 23954320, PMCID: PMC3807825, PII: S0730-725X(13)00233-6, DOI: 10.1016/j.mri.2013.07.002, ISSN: 1873-5894.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23954320.
  • Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer [print-electronic]. 2013 Jul 7/1/2013; 119(13): 2375-82. PMID: 23575918, PMCID: PMC3687009, DOI: 10.1002/cncr.28016, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23575918.
  • Atuegwu NC, Arlinghaus LR, Li X, Chakravarthy AB, Abramson VG, Sanders ME, Yankeelov TE. Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy. Transl Oncol [electronic-print]. 2013 Jun; 6(3): 256-64. PMID: 23730404, PMCID: PMC3660793, ISSN: 1936-5233.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23730404.
  • Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 2013 Mar; 200(3): 475-83. PMID: 23436834, PMCID: PMC3652983, PII: 200/3/475, DOI: 10.2214/AJR.12.9049, ISSN: 1546-3141.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23436834.
  • Iams W, Beckermann KE, Neff AT, Mayer IA, Abramson VG. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Med. Oncol [print-electronic]. 2013; 30(2): 568. PMID: 23564368, PMCID: PMC3774143, DOI: 10.1007/s12032-013-0568-x, ISSN: 1559-131X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23564368.
  • Abramson RG, Arlinghaus LR, Weis JA, Li X, Dula AN, Chekmenev EY, Smith SA, Miga MI, Abramson VG, Yankeelov TE. Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. Breast Cancer (Dove Med Press). 2012 Oct; 2012(4): 139-54. PMID: 23154619, PMCID: PMC3496377, DOI: 10.2147/BCTT.S35882, ISSN: 1179-1314.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23154619.
  • Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Magn Reson Med [print-electronic]. 2012 Jul; 68(1): 261-71. PMID: 22127821, PMCID: PMC3291742, DOI: 10.1002/mrm.23205, ISSN: 1522-2594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22127821.
  • Abramson VG, Mayer IA. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Ther Adv Med Oncol. 2012 May; 4(3): 139-47. PMID: 22590487, PMCID: PMC3349077, PII: 10.1177_1758834012440834, DOI: 10.1177/1758834012440834, ISSN: 1758-8359.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22590487.
  • Abramson VG, Mayer IA. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Curr Treat Options Oncol. 2011 Dec; 12(4): 403-11. PMID: 21918859, DOI: 10.1007/s11864-011-0164-2, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21918859.
  • Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. Phys Med Biol [print-electronic]. 2011 Sep 9/7/2011; 56(17): 5753-69. PMID: 21841212, PMCID: PMC3176673, PII: S0031-9155(11)87575-5, DOI: 10.1088/0031-9155/56/17/018, ISSN: 1361-6560.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21841212.
  • Arlinghaus LR, Welch EB, Chakravarthy AB, Xu L, Farley JS, Abramson VG, Grau AM, Kelley MC, Mayer IA, Means-Powell JA, Meszoely IM, Gore JC, Yankeelov TE. Motion correction in diffusion-weighted MRI of the breast at 3T. J Magn Reson Imaging. 2011 May; 33(5): 1063-70. PMID: 21509862, PMCID: PMC3081111, DOI: 10.1002/jmri.22562, ISSN: 1522-2586.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21509862.
  • Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Res. 2010 Apr; 30(4): 1279-85. PMID: 20530440, PMCID: PMC3874215, PII: 30/4/1279, ISSN: 1791-7530.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20530440.